TY - JOUR
T1 - Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients
AU - Rhee, Eugene P.
AU - Guallar, Eliseo
AU - Hwang, Seungyoung
AU - Kim, Noori
AU - Tonelli, Marcello
AU - Moe, Sharon M.
AU - Himmelfarb, Jonathan
AU - Thadhani, Ravi I.
AU - Powe, Neil R.
AU - Shafi, Tariq
N1 - Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background Uremic symptoms are major contributors to the poor quality of life among patients on dialysis, but whether their prevalence or intensity has changed over time is unknown. Methods We examined responses to validated questionnaires in two incident dialysis cohort studies, the Choices for Health Outcomes in Caring for ESRD (CHOICE) study (N926, 1995-1998) and the Longitudinal United States/Canada Incident Dialysis (LUCID) study (N428, 2011-2017). We determined the prevalence and severity of uremic symptoms - anorexia, nausea/vomiting, pruritus, sleepiness, difficulty concentrating, fatigue, and pain - in both cohorts. Results In CHOICE and LUCID, respectively, mean age of the participants was 58 and 60 years, 53% and 60% were male, and 28% and 32% were black. In both cohorts, 54% of the participants had diabetes. Median time from dialysis initiation to the symptoms questionnaires was 45 days for CHOICE and 77 days for LUCID. Uremic symptom prevalence in CHOICE did not change from baseline to 1-year follow-up and was similar across CHOICE and LUCID. Baseline symptom prevalence in CHOICE and LUCID was as follows: anorexia (44%, 44%, respectively), nausea/vomiting (36%, 43%), pruritus (72%, 63%), sleepiness (86%, 68%), difficulty concentrating (55%, 57%), fatigue (89%, 77%), and pain (82%, 79%). In both cohorts, >80% of patients had three or more symptoms and >50% had five or more symptoms. The correlation between individual symptoms was low (ρ<0.5 for all comparisons). In CHOICE, no clinical or laboratory parameter was strongly associated with multiple symptoms. Conclusions The burden of uremic symptoms among patients on dialysis is substantial and has not changed in the past 15 years. Improving quality of life will require identification of the factors that underlie the pathogenesis of uremic symptoms and better ways of removing the toxins that are responsible.
AB - Background Uremic symptoms are major contributors to the poor quality of life among patients on dialysis, but whether their prevalence or intensity has changed over time is unknown. Methods We examined responses to validated questionnaires in two incident dialysis cohort studies, the Choices for Health Outcomes in Caring for ESRD (CHOICE) study (N926, 1995-1998) and the Longitudinal United States/Canada Incident Dialysis (LUCID) study (N428, 2011-2017). We determined the prevalence and severity of uremic symptoms - anorexia, nausea/vomiting, pruritus, sleepiness, difficulty concentrating, fatigue, and pain - in both cohorts. Results In CHOICE and LUCID, respectively, mean age of the participants was 58 and 60 years, 53% and 60% were male, and 28% and 32% were black. In both cohorts, 54% of the participants had diabetes. Median time from dialysis initiation to the symptoms questionnaires was 45 days for CHOICE and 77 days for LUCID. Uremic symptom prevalence in CHOICE did not change from baseline to 1-year follow-up and was similar across CHOICE and LUCID. Baseline symptom prevalence in CHOICE and LUCID was as follows: anorexia (44%, 44%, respectively), nausea/vomiting (36%, 43%), pruritus (72%, 63%), sleepiness (86%, 68%), difficulty concentrating (55%, 57%), fatigue (89%, 77%), and pain (82%, 79%). In both cohorts, >80% of patients had three or more symptoms and >50% had five or more symptoms. The correlation between individual symptoms was low (ρ<0.5 for all comparisons). In CHOICE, no clinical or laboratory parameter was strongly associated with multiple symptoms. Conclusions The burden of uremic symptoms among patients on dialysis is substantial and has not changed in the past 15 years. Improving quality of life will require identification of the factors that underlie the pathogenesis of uremic symptoms and better ways of removing the toxins that are responsible.
KW - Dialysis
KW - Quality of Life
KW - Renal Dialysis
KW - Symptoms
KW - Uremia
UR - http://www.scopus.com/inward/record.url?scp=85088827658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088827658&partnerID=8YFLogxK
U2 - 10.34067/KID.0000072019
DO - 10.34067/KID.0000072019
M3 - Article
AN - SCOPUS:85088827658
SN - 2641-7650
VL - 1
SP - 86
EP - 92
JO - Kidney360
JF - Kidney360
IS - 2
ER -